A retrospective analysis of a large cohort of patients with diabetic macular edema showed high prevalence of bilateral ...

4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 ...

Second-generation anti-VEGF agents, like aflibercept 8 mg and faricimab, show improved efficacy and treatment durability in ...

DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years ...

Please provide your email address to receive an email when new articles are posted on . One specialist highlighted cases in which systemic treatments, such as corticosteroids, are better. Another ...

The optic cup and macula of a 24-year-old female. Image is released to Wikimedia commons with patient consent. Imaged with a non-mydriatic fundus camera at Pacific University College of Optometry.

David Eichenbaum, MD, FASRS, recalls an early-career case managing bilateral diabetic macular edema with frequent ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Brolucizumab ...

A dexamethasone implant significantly outperformed ranibizumab (Lucentis) and methotrexate for intravitreal treatment of persistent/recurrent uveitic macular edema, according to results of a ...

Vabysmo now covered across all three approved indications in the province, providing patients with a comprehensively funded option for their needs "This expansion in coverage for people with RVO in ...

Fluocinolone implants can slow diabetic retinopathy and delay proliferation in patients with diabetic macular edema, researchers say. Compared with antivascular endothelial growth factor (anti-VEGF) ...

August 10, 2012 — The US Food and Drug Administration (FDA) has approved ranibizumab (Lucentis, Genentech) intravitreal injection for the treatment of diabetic macular edema (DME), according to an ...